849925-01-5

Usage

Uses

Since the provided materials do not specify the uses of 3-(5-Piperidin-4-yl-1,2,4-oxadiazol-3-yl)pyridine, I can only infer potential applications based on the general properties of similar compounds. Here are some hypothetical uses:
Used in Pharmaceutical Industry:
3-(5-Piperidin-4-yl-1,2,4-oxadiazol-3-yl)pyridine could be used as a pharmaceutical agent for its potential biological activity. 3-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE's structure may allow it to interact with various biological targets, such as enzymes or receptors, which could be exploited for therapeutic purposes.
Used in Chemical Research:
In the field of chemical research, 3-(5-Piperidin-4-yl-1,2,4-oxadiazol-3-yl)pyridine might serve as a starting material or intermediate in the synthesis of more complex molecules with specific applications in various industries.
Used in Material Science:
3-(5-PIPERIDIN-4-YL-1,2,4-OXADIAZOL-3-YL)PYRIDINE could also be explored for its potential use in material science, where its unique structure might contribute to the development of new materials with specific properties, such as conductivity, magnetism, or luminescence.

Upstream product

• 100-54-9 pyridine-3-carbonitrile 
• 1594-58-7 nicotinamide oxime 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 1001467-24-8 tert-butyl 4-(3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl)piperidine-1-carboxylate 

Downstream Products

• 882047-21-4 C₃₃H₂₉N₇OS 

Relevant academic research and scientific papers

SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION

The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

Triazole alcohol antifungal compound with piperidine oxadiazole side chain and preparation method for compound and application of compound

The invention relates to the medical technical field and provides 1-(1H-1,2,4-triazole-1-yl)-2-(2,4-difluorophenyl)-3-(piperidine oxadiazole side chain substituted)-2-propanol compounds in one category. The compound comprises cis-trans-isomers thereof and any mixtures in the forms or pharmaceutical salts thereof. The chemical structural formula of the compound is represented by a formula (I). The invention further provides a preparation method for the compound and an application of the compound in preparing antifungal drugs. From an antifungal experiment, the compound provided by the invention has a very strong antifungal effect on various superficial fungi and deep fungi. Compared with existing clinically applied antifungal drugs such as fluconazole, the compound has the advantages of being efficient, low in toxicity and wide in antifungal spectrum, has relatively good activity on fluconazole drug-resistant bacteria and can be used for preparing antifungal drugs. The formula is shown in the description.

Discovery of highly potent triazole antifungal agents with piperidine-oxadiazole side chains

Due to increasing incidence and mortality of invasive fungal infections, discovery and development of new generations of antifungal agents represents a challenging task. On the basis of our previously reported triazole-benzyloxypiperidinyl lead compound, a series of novel triazole antifungal agents containing piperidine-oxadiazole side chains were rationally designed and synthesized. Most of the target compounds showed excellent inhibitory activity against clinically important fungal pathogens. In particular, compounds 6g (MIC = 0.031 μg mL-1) and 11b (MIC = 0.016 μg mL-1) were highly active against Candida albicans including fluconazole-resistant strains. Moreover, they showed inhibitory activity against hyphal formation with low toxicity, which were promising leads for further development. This journal is